InflaRx IFRX
NASDAQ IFRX
$2.05 -0.04 (-1.91%)
As of: Sep 10, 2026 · 3:59 PM EDT

InflaRx (IFRX) Share-based Compensation (2017 - 2026)

InflaRx's (IFRX) quarterly Share-based Compensation came in at $687392.9 in Q2 2026, down 45.22% year-over-year from $1.3 million in Q2 2025, and down 37.61% quarter-over-quarter from $1.1 million in Q1 2026.

Analysis

InflaRx (IFRX) Share-based Compensation (2017 - 2026) Analysis & Trends

InflaRx has disclosed Share-based Compensation across 10 years of filings, most recently posting $687392.9 for Q2 2026.

  • In Q2 2026, Share-based Compensation fell 45.22% year-over-year to $687392.9; the TTM figure through Jun 2026 stood at $2.8 million (down 43.58% YoY), while the FY2025 annual figure was $5.0 million, up 15.58% from the prior year.
  • Share-based Compensation came in at $687392.9 for Q2 2026 at InflaRx, down from $1.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.8 million in Q1 2022 to a low of $302937.7 in Q4 2025.
  • Average Share-based Compensation over 5 years is $1.2 million, with a median of $1.0 million recorded in 2022.
  • Year-over-year, Share-based Compensation surged 95.98% in 2022 and tumbled 57.76% in 2026.
  • Over 5 years, Share-based Compensation stood at $472716.3 in 2022, then climbed by 3.11% to $487398.6 in 2023, then retreated by 25.48% to $363215.6 in 2024, then retreated by 16.6% to $302937.7 in 2025, then soared by 126.91% to $687392.9 in 2026.
  • Per Business Quant data, the three most recent Share-based Compensation figures were $687392.9 in Q2 2026, $1.1 million in Q1 2026, and $302937.7 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 86.63 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 77.40 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 83.34 Mn
10 InflaRx 139.29 Mn -44.96 Mn 2.74 Mn 687,392.90
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 687,392.90
Mar 31, 2026 1.10 Mn
Dec 31, 2025 302,937.67
Sep 30, 2025 696,615.38
Jun 30, 2025 1.25 Mn
Mar 31, 2025 2.61 Mn
Dec 31, 2024 363,215.58
Sep 30, 2024 716,142.35
Jun 30, 2024 1.31 Mn
Mar 31, 2024 2.02 Mn
Dec 31, 2023 487,398.63
Sep 30, 2023 786,064.65
Jun 30, 2023 1.12 Mn
Mar 31, 2023 1.30 Mn
Dec 31, 2022 472,716.31
Sep 30, 2022 920,090.66
Jun 30, 2022 2.28 Mn
Mar 31, 2022 2.84 Mn
Dec 31, 2021 581,838.50
Sep 30, 2021 1.34 Mn